T1	PrimaryOutcome 40 187	timing to achieve viral RNA negative conversion for SARS-CoV-2 in all three specimens, including nasopharyngeal swabs, throat swabs and stool swabs
T2	SecondaryOutcome 365 399	timing when CT imaging improvement
T3	OutcomeDefinition 424 481	mainly based on the size and density reduction of lesions
R1	DefinedAs Arg1:T2 Arg2:T3	
T4	OtherOutcome 504 535	adverse events during treatment
T5	OtherOutcome 537 558	severe adverse events
T6	OtherOutcome 564 602	premature discontinuation of treatment
T7	OutcomeDefinition 624 724	classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events
R2	DefinedAs Arg1:T4 Arg2:T7	
